stated, we expect to achieve full-year positive gap net income and further expansion of adjusted EBITDA margins compared to 2025. The expected improvement in net income and adjusted EBITDA margins from 2025 is primarily driven by expecte

May 8, 2026 / receipt

Clearly, we're really focused on any kind of discretionary spending, particularly travel, and putting a pretty fine filter on who goes where and why.

Feb 29, 2024 / receipt, needs a key / Ron, CEO | earnings call 2024-02-29 | transcript f9acf57a-cd8e-49bb-a771-1aa4e595915b | chars 22850-22999 | segment 23

The decrease was largely due to reduced personnel expenses from the reduction in force in Q3 2023, decreased consulting costs, and a reduction in travel expenses.

Feb 29, 2024 / receipt, needs a key / Troy Wichterman, CFO | earnings call 2024-02-29 | transcript f9acf57a-cd8e-49bb-a771-1aa4e595915b | chars 10591-10753 | segment 11

In addition, as remarked in my script, we had the increase in cell processing revenue, and then we did a control on discretionary expenses, such as consulting costs and travel.

Feb 29, 2024 / receipt, needs a key / Troy Wichterman, CFO | earnings call 2024-02-29 | transcript f9acf57a-cd8e-49bb-a771-1aa4e595915b | chars 14714-14890 | segment 15

In addition, we eliminated discretionary travel and marketing expenses.

Nov 9, 2023 / receipt, needs a key / Troy Wisherman, CFO | earnings call 2023-11-09 | transcript 7c307dbf-1a46-4454-8063-84ed020babf7 | chars 10090-10161 | segment 10

17-20% revenue growth expected for FY 2026 with positive net income (GAAP) for the full year and continued expansion of adj. EBITDA margin

ir_statement / Aug 25, 2026 / receipt

17-20% revenue growth expected for FY 2026 with positive net income (GAAP) for the full year and continued expansion of adj. EBITDA margin

ir_statement / Aug 25, 2026 / receipt

continued expansion of adj. EBITDA margin

ir_statement / Aug 25, 2026 / receipt